Annexon, Inc. (NASDAQ:ANNX) CFO Jennifer Lew Sells 6,912 Shares

Annexon, Inc. (NASDAQ:ANNX) CFO Jennifer Lew sold 6,912 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $2.92, for a total value of $20,183.04. Following the completion of the transaction, the chief financial officer now owns 77,770 shares in the company, valued at approximately $227,088.40. This represents a 8.16 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Jennifer Lew also recently made the following trade(s):

• On Thursday, February 13th, Jennifer Lew sold 1,786 shares of Annexon stock. The stock was sold at an average price of $2.98, for a total value of $5,322.28.

Annexon Trading Down 0.7 %

Annexon stock opened at $2.81 on Friday. The firm has a market capitalization of $299.52 million, a P/E ratio of -2.68 and a beta of 1.07. The business has a 50-day moving average of $4.26 and a 200-day moving average of $5.55. Annexon, Inc. has a 1 year low of $2.63 and a 1 year high of $8.40.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ANNX. TFG Asset Management GP Ltd raised its holdings in Annexon by 78.5% in the fourth quarter. TFG Asset Management GP Ltd now owns 1,400,000 shares of the company’s stock worth $7,182,000 after purchasing an additional 615,645 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Annexon in the 4th quarter valued at $252,000. Shay Capital LLC acquired a new stake in Annexon during the 4th quarter worth $159,000. Sphera Funds Management LTD. acquired a new stake in Annexon during the 4th quarter worth $6,377,000. Finally, Rafferty Asset Management LLC lifted its holdings in Annexon by 23.5% during the fourth quarter. Rafferty Asset Management LLC now owns 218,369 shares of the company’s stock worth $1,120,000 after acquiring an additional 41,544 shares in the last quarter.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Annexon in a research note on Friday, November 15th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Annexon in a research note on Tuesday, December 17th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $16.00 target price on shares of Annexon in a report on Friday, November 15th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Annexon has an average rating of “Buy” and a consensus target price of $15.80.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.